Drug Profile


Alternative Names: MK-0859

Latest Information Update: 23 Dec 2016

Price : $50

At a glance

  • Originator Merck & Co
  • Developer Merck & Co; University of Oxford
  • Class Antihyperlipidaemics; Oxazolidinones; Small molecules
  • Mechanism of Action Cholesterol ester transfer protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Atherosclerosis; Hypercholesterolaemia; Hyperlipidaemia; Hyperlipoproteinaemia type IIa

Most Recent Events

  • 12 Nov 2016 Pharmacodynamics data from a phase I trial in Hypercholesterolaemia presented at the 89th Annual Scientific Sessions of the American Heart Association (AHA-2016)
  • 10 Oct 2016 Cambridge University Hospitals NHS Foundation Trust and British Heart Foundation Cambridge Centre of Excellence plan the observational REVEAL-Vasc sub-study for Atherosclerosis (Adjunctive treatment) in United Kingdom (PO) (NCT02931188)
  • 04 Aug 2015 The phase III DEFINE trial for Atherosclerosis (Adjunctive treatment) is ongoing in USA, Australia, Austria, China, Finland, France, Germany, Hungary, Israel, Malaysia, Mexico, Netherlands, Norway, Russia, Sweden and Spain (NCT00685776)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top